Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

INTRODUCTION: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies h...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Genta, Nakamura, Masanao, Yamamura, Takeshi, Maeda, Keiko, Sawada, Tsunaki, Ishikawa, Eri, Furukawa, Kazuhiro, Iida, Tadashi, Mizutani, Yasuyuki, Yamao, Kentaro, Ishikawa, Takuya, Ishizu, Yoji, Honda, Takashi, Ishigami, Masatoshi, Kawashima, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601947/
https://www.ncbi.nlm.nih.gov/pubmed/37901340
http://dx.doi.org/10.1159/000531497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601947/
https://www.ncbi.nlm.nih.gov/pubmed/37901340
http://dx.doi.org/10.1159/000531497

Ejemplares similares